MIRA PHARMACEUTICALS, INC. - 8-K Filing
Mira Pharmaceuticals announced the publication of a peer-reviewed manuscript on SKNY-1, its investigational drug candidate for obesity and nicotine addiction. The study in the International Journal of Molecular Sciences reported preclinical findings showing that oral administration of SKNY-1 led to up to 30% weight reduction in high-dose groups over six days in an MC4R-deficient zebrafish model. (Items: 8.01 Other Events On May 13, 2026, MIRA Pharmaceuticals, Inc)
Tickers: $MIRA